Fig. 3: Application of the two-step workflow to an in vivo clinical cohort. | Nature Communications

Fig. 3: Application of the two-step workflow to an in vivo clinical cohort.

From: Two-step detection of Lewy body pathology via smell-function testing and CSF α-synuclein seed amplification

Fig. 3

The two-step workflow applied to an in vivo clinical cohort. a Distribution of model-derived probabilities for cortical Lewy body pathology (LBP) based on a logistic regression model including UPSIT scores, age, and sex as predictors, trained on the autopsy dataset. A probability threshold corresponding to 95% sensitivity, derived from the autopsy dataset, was used to classify individuals as low- (blue dots) or high- (red dots) risk for cortical LBP. b Performance metrics of the UPSIT-based risk classification groups for predicting CSF α-syn SAA status, including accuracy, positive predictive value (PPV), and negative predictive value (NPV). c Reduction in the number of CSF tests required using the two-step workflow. Error bars correspond to 95% CIs based on 1000 iterations of model development and classification. 1209 PPMI participants were included in the analyses. αsyn alpha-synuclein, CSF cerebrospinal fluid, NPV negative predictive value, PPV positive predictive value, SAA seed amplification assay.

Back to article page